Want to see DXR full AI Analyst Report?
Daxor (DXR) AI Stock Analysis
Daxor
(NASDAQ:DXR)
The score is driven primarily by mixed financial quality: a very strong, low-debt balance sheet helps, but volatile revenue and inconsistent, often negative cash flow reduce confidence in earnings durability. Technicals are supportive with the stock trading above key moving averages and positive MACD, and valuation looks reasonable with a low P/E, partially offsetting the operating and cash-flow risks.
Daxor (DXR) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $53.71M
- Dividend Yield
- ―
- Average Volume (3M)
- 21.30K
- Price to Earnings (P/E)
- 7.5
- Beta (1Y)
- 0.62
- Revenue Growth
- -85.48%
- EPS Growth
- 234.88%
- Country
- US
- Employees
- 37
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Daxor Business Overview & Revenue Model
Company Description
Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument off...
Daxor Earnings Call Summary
The earnings call presented a robust performance with significant revenue growth, successful strategic acquisitions, and expanded clinical partnerships. Despite a delay in FDA approval and a decrease in unrealized appreciation, the company showcased strong momentum and promising developments for the future.
Q4-2024 Updates
Positive Updates
Negative Updates
Company Guidance
During the Daxor Corporation Conference Call for the 2024 fiscal year, management provided several key financial and operational metrics. As of December 31st, 2024, the company's net assets increased to $36,789,893 or $7.25 per share, compared to $34,010,384 or $7.08 per share at the end of 2023. The company's net income included net dividend income of $104,115 and net realized gains on investments of $1,359,163, offset by a net decrease in unrealized appreciation of $1,148,350. The company invested $1,614,124 into its operating division for research and development, sales, and production facilities in anticipation of a 2025 product launch. Additionally, Daxor achieved a cash flow breakeven in early 2025, excluding costs related to stock-based compensation, depreciation, amortization, or CapEx. Revenue increased by 116.5% from 2023 to 2024, with a further year-on-year increase of over 100% in the first two months of 2025. The company also reported significant clinical progress with the adoption of its Blood Volume Analyzer (BVA) technology across various medical disciplines, laying the groundwork for further growth and innovation in healthcare solutions.
Daxor Financial Statement Overview
Summary
Balance sheet strength (very low leverage and a sizable equity cushion) supports a higher score, but it is offset by unstable operations: revenue has been volatile with a sharp 2025 decline after a 2023 spike, and cash generation is weak with negative operating and free cash flow in multiple years, suggesting uneven cash conversion and elevated execution risk.
Income Statement
56NeutralBalance Sheet
84Very PositiveCash Flow
34Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 154.87K | 503.42K | 2.13M | 34.59M | -353.36K | -2.62M |
| Gross Profit | -164.96K | 188.74K | 2.13M | 34.41M | -1.44M | -3.62M |
| EBITDA | 6.23M | 9.19M | 2.06M | 1.12M | 6.11M | 5.51M |
| Net Income | 6.23M | 9.17M | 536.33K | 280.64K | 5.18M | 4.75M |
Balance Sheet | ||||||
| Total Assets | 51.86M | 46.01M | 36.63M | 34.87M | 30.26M | 24.98M |
| Cash, Cash Equivalents and Short-Term Investments | 5.79M | 0 | 0 | 0 | 0 | 710.70K |
| Total Debt | 0 | 112.00K | 729.97K | 755.66K | 1.23M | 3.02M |
| Total Liabilities | 23.60K | 122.59K | 840.30K | 858.76K | 1.29M | 3.83M |
| Stockholders Equity | 51.83M | 45.89M | 35.79M | 34.01M | 28.97M | 21.15M |
Cash Flow | ||||||
| Free Cash Flow | -2.81M | -604.42K | 25.69K | -3.66M | -769.30K | -2.76M |
| Operating Cash Flow | -2.81M | -604.42K | 25.69K | -3.66M | -769.30K | -2.76M |
| Investing Cash Flow | -5.37M | 1.18M | 1.94M | 2.75M | 2.69M | 74.76K |
| Financing Cash Flow | 8.18M | -570.94K | -25.69K | 3.66M | 58.60K | 2.85M |
Daxor Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DXR, the sentiment is Negative. The current price of 9.20 is below the 20-day moving average (MA) of 9.82, below the 50-day MA of 10.43, and below the 200-day MA of 10.72, indicating a bearish trend. The MACD of -0.46 indicates Positive momentum. The RSI at 35.46 is Neutral, neither overbought nor oversold. The STOCH value of 24.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DXR.
Daxor Peers Comparison
Overall Rating
MMSI71Outperform
PDEX68Neutral- DXR65Neutral
FEMY45Neutral
MLSS39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| MMSI | 71Outperform | $5.17B | 32.06 | 9.65% | ― | 9.34% | 33.77% |
| PDEX | 68Neutral | $188.04M | 15.55 | 26.18% | ― | 13.31% | 9.26% |
| DXR | 65Neutral | $53.71M | 7.48 | 12.75% | ― | -85.48% | 234.88% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| FEMY | 45Neutral | $11.47M | -0.30 | -225.98% | ― | 21.86% | 73.27% |
| MLSS | 39Underperform | $27.61M | -6.38 | -149.08% | ― | 3.72% | 43.78% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| DXR | Daxor Corporation | 9.20 | -3.89 | -29.72% | |
| MMSI | Merit Medical | 86.24 | -1.10 | -1.26% | |
| PDEX | Pro-dex | 58.16 | 22.26 | 62.01% | |
| MLSS | Milestone Scientific Inc | 0.30 | -0.11 | -27.45% | |
| FEMY | Femasys, Inc. | 1.37 | -11.77 | -89.58% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Sep 25, 2026